![Rick Pollack Perspective 900x400 12-2023](/sites/default/files/2023-12/Rick-Pollack-Perspective-900x400px-12-23.png)
Combining the anti-inflammatory drug baricitinib with the antiviral drug remdesivir reduced the median recovery time for hospitalized COVID-19 patients from eight to seven days, according to clinical trial results published in the New England Journal of Medicine.